Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Conditions
Interventions
Bevacizumab
FOLFIRI
+1 more
Locations
1
United States
Summit Health Cancer Center
Florham Park, New Jersey, United States
Start Date
April 30, 2026
Primary Completion Date
August 30, 2027
Completion Date
April 30, 2030
Last Updated
April 24, 2026
NCT07224724
NCT03829462
NCT02792478
NCT04745130
NCT02069704
NCT02547480
Lead Sponsor
Oncolytics Biotech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions